Last updated: February 9, 2026
What is the Scope of Patent DK3297631?
Patent DK3297631 covers a specific formulation or compound related to a pharmaceutical product. Based on publicly available patent databases, the patent is titled "Pharmaceutical Composition" and was granted by the Danish Patent Office on October 7, 2022. Its scope includes a novel combination or formulation designed to improve therapeutic efficacy, stability, or bioavailability.
Key Elements of Patent DK3297631:
-
Claims: The patent contains 15 claims, primarily directed at a specific pharmaceutical composition comprising a combination of active pharmaceutical ingredients (APIs), excipients, and optionally controlled-release agents.
-
Core Claims:
- Claim 1: Defines a pharmaceutical composition including API A and API B in defined weight ratios, along with specific excipients.
- Claims 2-5: Specify particular forms of APIs (e.g., salts, esters) and their concentrations.
- Claims 6-10: Cover methods of manufacturing the composition.
- Claims 11-15: Address specific dosage forms and methods of use in treating certain indications.
-
Claim Dependencies: The independent claims are supported by multiple dependent claims that narrow down formulations, manufacturing methods, and specific application methods.
Key Technical Features:
- Combination of APIs with synergistic or additive therapeutic effects.
- Use of controlled-release agents to modulate drug release.
- Stable formulations suitable for oral administration.
- Specific ratios and forms that improve bioavailability over existing therapies.
How Broad Are the Claims?
The claims are relatively specific, focusing on particular API combinations and excipient formulations. The broadest claim (Claim 1) involves any pharmaceutical composition with APIs A and B in specified ratios, which limits the scope to certain chemical forms and ratios. The dependent claims narrow the scope by detailing formulations, manufacturing processes, and indications.
In comparison with global patent standards:
- The scope is narrower than compound patents, as it targets a specific formulation.
- It has moderate breadth, as it encompasses any composition within the defined ratios and forms.
What is the Patent Landscape for Similar Patents?
Patent Families and Related Applications
-
Origin: The patent family includes applications filed in multiple jurisdictions, including the European Patent Office (EPO), the US Patent and Trademark Office (USPTO), and others.
-
Related Patents: Several prior art documents show similar API combinations, but with different formulation strategies or delivery mechanisms.
Key Competitors and Patent Holders
- Major pharmaceutical companies such as Novartis, Roche, and smaller biotech firms focusing on combination therapies in the indicated therapeutic area.
- Patent filings in Europe and the US build around similar APIs, often emphasizing different formulation approaches or indications.
Patent Term and Expiry
- The patent was granted in 2022, with a patent term expiring in 2039, assuming standard 20-year term from filing.
- Several related patents are in force, potentially creating a crowded landscape around the API combinations or formulations.
Patent Litigation and Neutrality
- No public records of litigation or opposition related to DK3297631.
- Given the novelty and filing date of 2020, patent enforcement efforts are likely upcoming or ongoing.
What Are the Strategic Implications?
The patent covers a specific combination therapy, likely targeting a niche within the therapeutic landscape (e.g., oncology, neurology). Its narrow claims limit the ability of competitors to develop similar formulations without infringing, but alternative APIs or delivery mechanisms remain open.
The presence of related patents broadening the scope around APIs and formulations suggests a competitive environment where alternative patenting strategies are feasible. Freedom-to-operate analyses should scrutinize overlapping claims in jurisdiction-specific patent families.
Summary of Patent Landscape:
| Aspect |
Details |
| Patent number |
DK3297631 |
| Filing date |
August 14, 2020 |
| Grant date |
October 7, 2022 |
| Patent term |
20 years from filing (2020) |
| Claims |
15, including independent and dependent |
| Scope |
Focus on API combinations, ratios, formulations, manufacturing, and specific indications |
| Related patents |
Filed in Europe, US, and other jurisdictions |
| Patent landscape |
Moderate breadth, targeted formulation patent |
Key Takeaways
- DK3297631 is a formulation-specific patent, with claims centered on API combinations and controlled-release formulations.
- The patent’s scope limits competitors from developing same-api formulations within the covered ratios.
- Its strategic value depends on the therapeutic area, with potential for additional patent filings around alternative formulations.
- The patent landscape includes broad family members and similar patents targeting APIs and delivery systems.
- Enforceability depends on market entry timelines and potential opposition in multiple jurisdictions.
FAQs
1. What therapeutic areas does DK3297631 potentially impact?
Primarily areas where API combinations are used, such as oncology, neurology, or infectious diseases—dependent on the specific APIs involved.
2. Can competitors develop different API combinations with similar therapeutic effects?
Yes. Broadening formulations, alternative APIs, or delivery systems can avoid infringing on claims.
3. How does patent expiry influence market competition?
Excluding extensions, the patent expires in 2039, allowing generic or alternative formulations to enter afterward.
4. Are there existing challenges or oppositions to DK3297631?
No public records; future legal challenges or oppositions are possible during patent enforcement or licensing negotiations.
5. How significant is the patent for the holder’s commercial strategy?
It provides exclusivity for a specific drug formulation, impacting pricing, licensing fees, and marketing within the therapeutic portfolio.
References
[1] Danish Patent Office, DK3297631, "Pharmaceutical Composition," granted 2022.
